Skip to main content
SearchLoginLogin or Signup

Establishment of a Pilot Drug Therapy Monitoring Service for Patients Switching from Efavirenz- to Dolutegravir-Based ARV Drugs in Zimbabwe

Published onJun 13, 2023
Establishment of a Pilot Drug Therapy Monitoring Service for Patients Switching from Efavirenz- to Dolutegravir-Based ARV Drugs in Zimbabwe

Introduction 

Routine drug therapy monitoring addresses variation in pharmacologic responses among patients due to factors affecting absorption, distribution, and clearance of drugs. In resource-constrained settings e.g., Zimbabwe, drug therapy monitoring is hampered by expertise, technology and financial constraints. Therefore, this capacity building effort, obligated by the University of Zimbabwe’s Education 5.0 strategy that seeks to promote among other pillars research, innovation and industrialization , sought to establish a drug therapy monitoring service for patients switching ARV drugs in Zimbabwe. 

Justification 

In collaboration with the AIDS and TB directorate in the Ministry of Health and Child Care, the University of Zimbabwe’s International Pharmacology Specialty Laboratory (UZ-IPSL) mobilized resources for drug therapy monitoring. This complements drug surveillance efforts by the Medicines Control Authority of Zimbabwe and improves the country’s pharmaceutical profile.  

 Objectives 

1. To establish a key stakeholder collaboration to enable implementation of drug therapy monitoring in Zimbabwe 

2. To source financial, and technological resources for drug therapy monitoring.  

Materials and Methods 

- Identification of equipment, methods and selecting collaborating scientists, policy makers and pharmacologists. 

- Applying for sponsorship from the Global Fund through the Quality Assurance Task Force (QATF) 

- Drafting a memorandum of agreement (MOA) between UZ-IPSL and the Medicines Control Authority of Zimbabwe (as the sub-recipient of the Global Fund grant and Secretariat to the QATF) 

Results 

-Assembled collaborators and technologies for drug determination   

-Awarded UNDP grant for method development and for study of 500 patients. 

-Signed MOA between UZ-IPSL and MCAZ 

Discussion, and Conclusion 

Innovation, collaborations and capacity building are essential in supporting improvements in health systems in resource constrained settings.  

 References 

1. Batista CJB, et al. The Brazilian experience of implementing the active pharmacovigilance of dolutegravir, Medicine (Baltimore). 2019 Mar; 98(10): e14828. 

2. Castellino S, et al. Metabolism, excretion, and mass balance of the HIV-1 integrase inhibitor dolutegravir in humans. Antimicrob Agents Chemother. 2013;57(8):3536–3546. doi:10.1128/AAC.00292-13

Comments
0
comment
No comments here
Why not start the discussion?